Licia Grazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/734446/publications.pdf

Version: 2024-02-01

232 5,623 38
papers citations h-index

236 236 3350
all docs docs citations times ranked citing authors

60

g-index

#	Article	IF	Citations
1	The use of pharmacologic prophylaxis for migraine in pediatric and adolescent age: a crucial concern. Neurological Sciences, 2022, 43, 2121.	0.9	1
2	Management of chronic migraine with medication overuse by web-based behavioral program during the COVID-19 emergency: results at 12Âmonths. Neurological Sciences, 2022, 43, 1583-1585.	0.9	7
3	Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center. Neurological Sciences, 2022, 43, 5717-5724.	0.9	5
4	Mindfulness and other behavioral approaches. Neurological Sciences, 2022, 43, 5745-5747.	0.9	3
5	Feasibility and effect of mindfulness approach by web for chronic migraine and high-frequency episodic migraine without aura at in adolescents during and after COVID emergency: preliminary findings. Neurological Sciences, 2022, 43, 5741-5744.	0.9	4
6	Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine. Neurological Sciences, 2021, 42, 389-397.	0.9	26
7	Erenumab in the prevention of highâ€frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective realâ€ife study. Headache, 2021, 61, 363-372.	1.8	7 5
8	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients―Multi-Centre Observational Study. International Journal of Environmental Research and Public Health, 2021, 18, 340.	1.2	14
9	Lessons from lockdown â€" behavioural interventions in migraine. Nature Reviews Neurology, 2021, 17, 195-196.	4.9	5
10	Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches. International Journal of Environmental Research and Public Health, 2021, 18, 1503.	1.2	27
11	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and Therapy, 2021, 10, 637-650.	1.5	12
12	Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project. Neurological Sciences, 2021, 42, 5277-5288.	0.9	14
13	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	0.9	18
14	Withdrawal failure in patients with chronic migraine and medication overuse headache. Acta Neurologica Scandinavica, 2021, 144, 408-417.	1.0	6
15	Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVIDâ€19 pandemic: Lessons from a tertiary headache center in Milan—6â€month results. Headache, 2021, 61, 961-962.	1.8	7
16	Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation. Headache, 2021, 61, 895-905.	1.8	18
17	Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A realâ€life perspective from the Italian chROnic migraiNe (IRON) project. Headache, 2021, 61, 936-950.	1.8	6
18	Longâ€term (48Âweeks) effectiveness, safety, and tolerability of erenumab in the prevention of highâ€frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache, 2021, 61, 1351-1363.	1.8	62

#	Article	IF	CITATIONS
19	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. Pain and Therapy, 2021, 10, 1605-1618.	1.5	8
20	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. International Journal of Environmental Research and Public Health, 2021, 18, 246.	1.2	18
21	Global Burden of Headache Disorders in Children and Adolescents 2007–2017. International Journal of Environmental Research and Public Health, 2021, 18, 250.	1.2	36
22	Effect of a Mindfulness-Based Intervention for Chronic Migraine and High Frequency Episodic Migraine in Adolescents: A Pilot Single-Arm Open-Label Study. International Journal of Environmental Research and Public Health, 2021, 18, 11739.	1.2	5
23	The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patientâ€derived data. European Journal of Neurology, 2020, 27, 62.	1.7	27
24	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics, 2020, 20, 1275-1286.	1.4	14
25	Migraine and prophylaxis. Neurological Sciences, 2020, 41, 383-384.	0.9	0
26	Mindfulness as an add-on treatment for patients with chronic migraine and medication overuse: a preliminary analysis. Neurological Sciences, 2020, 41, 469-471.	0.9	6
27	Effectiveness of mindfulness by smartphone, for patients with chronic migraine and medication overuse during the Covid-19 emergency. Neurological Sciences, 2020, 41, 461-462.	0.9	10
28	I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children. Cephalalgia, 2020, 40, 1459-1473.	1.8	43
29	No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial. Cephalalgia, 2020, 40, 1202-1211.	1.8	29
30	Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!. Headache, 2020, 60, 804-806.	1.8	7
31	Disability, Quality of Life, and Socioeconomic Burden of Cluster Headache: A Critical Review of Current Evidence and Future Perspectives. Headache, 2020, 60, 809-818.	1.8	30
32	HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Workâ€Related Disability in Patients With Migraine?. Headache, 2020, 60, 497-504.	1.8	6
33	The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVIDâ€19 Pandemic: Lessons From a Tertiary Headache Center in Milan, Italy. Headache, 2020, 60, 1463-1464.	1.8	12
34	Deeper inside the Experience of Pediatric Headache: A Narrative Study. Journal of Behavioral and Brain Science, 2020, 10, 432-454.	0.2	2
35	Neuromodulation and Other Non-pharmacological Approaches in Tension-Type Headache. Headache, 2020, , 157-172.	0.2	0
36	Onabotulinumtoxinâ€A in Chronic Migraine: Should Timing and Definition of Nonâ€Responder Status Be Revised? Suggestions From a Realâ€Life Italian Multicenter Experience. Headache, 2019, 59, 1300-1309.	1.8	16

#	Article	IF	Citations
37	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	2.5	116
38	Chronic migraine and medication overuse: which strategy for a complex scenario. Neurological Sciences, 2019, 40, 175-176.	0.9	3
39	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. Journal of Headache and Pain, 2019, 20, 26.	2.5	61
40	ACT for migraine: effect of acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: preliminary data of a phase-II, multicentric, randomized, open-label study. Neurological Sciences, 2019, 40, 191-192.	0.9	24
41	Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine. Neurological Sciences, 2019, 40, 201-202.	0.9	2
42	International Clinical Collaboration in Headache Medicine: The International Visiting Scholars Program. Headache, 2019, 59, 446-449.	1.8	1
43	A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache. Cephalalgia, 2019, 39, 655-664.	1.8	26
44	Pharmacotherapy for acute migraines in children and adolescents. Expert Opinion on Pharmacotherapy, 2019, 20, 455-463.	0.9	12
45	Establishment of an Italian chronic migraine database: a multicenter pilot study. Neurological Sciences, 2018, 39, 933-937.	0.9	7
46	A Short Review of the Non-invasive Transcutaneous Pericranial Electrical Stimulation Techniques and their Application in Headache. Current Pain and Headache Reports, 2018, 22, 4.	1.3	6
47	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	1.4	24
48	Atypical Facial and Head Pain in Childhood and Adolescence. Current Pain and Headache Reports, 2018, 22, 43.	1.3	3
49	The importance of specific rehabilitation for an obese patient with idiopathic intracranial hypertension: a case report. International Journal of Rehabilitation Research, 2018, 41, 183-185.	0.7	0
50	Non-pharmacological Approaches for Headaches in Young Age: An Updated Review. Frontiers in Neurology, 2018, 9, 1009.	1.1	21
51	Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. Journal of Headache and Pain, 2018, 19, 85.	2.5	19
52	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	2.5	34
53	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	2.5	18
54	Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. Current Pain and Headache Reports, 2018, 22, 71.	1.3	13

#	Article	IF	CITATIONS
55	Behavioral Approaches for Primary Headaches: Recent Advances. Headache, 2018, 58, 913-925.	1.8	36
56	OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience. Neurological Sciences, 2018, 39, 171-172.	0.9	6
57	Headache frequency and symptoms of depression as predictors of disability in patients with idiopathic intracranial hypertension. Neurological Sciences, 2018, 39, 139-140.	0.9	11
58	The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it?. Neurological Sciences, 2018, 39, 125-127.	0.9	9
59	Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results and changes in catastrophising attitude. Preliminary data. Neurological Sciences, 2018, 39, 173-174.	0.9	5
60	Gender and education inequalities in the cost of medication-overuse headache. Neurological Sciences, 2018, 39, 117-119.	0.9	5
61	Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurologica Scandinavica, 2018, 138, 515-522.	1.0	36
62	A Qualitative Study On Patients With Chronic Migraine With Medication Overuse Headache: Comparing Frequent And Nonâ€Frequent Relapsers. Headache, 2018, 58, 1373-1388.	1.8	19
63	The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire. Neurological Sciences, 2018, 39, 131-133.	0.9	4
64	Mindfulness meditation for chronic migraine in pediatric population: a pilot study. Neurological Sciences, 2018, 39, 111-113.	0.9	21
65	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.5	186
66	Value of treatment of headache patients and need to improve headache patients' journey. Neurological Sciences, 2018, 39, 115-116.	0.9	4
67	Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. Journal of Headache and Pain, 2017, 18, 15.	2.5	66
68	Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. Neurological Sciences, 2017, 38, 141-143.	0.9	8
69	Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. Neurological Sciences, 2017, 38, 197-199.	0.9	35
70	Mindfulness and pharmacological prophylaxis have comparable effect on biomarkers of inflammation and clinical indexes in chronic migraine with medication overuse: results at 12Âmonths after withdrawal. Neurological Sciences, 2017, 38, 173-175.	0.9	19
71	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. Journal of Headache and Pain, 2017, 18, 66.	2.5	27
72	Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurological Sciences, 2017, 38, 169-171.	0.9	9

#	Article	IF	Citations
73	Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurological Sciences, 2017, 38, 3-6.	0.9	21
74	Predictors of 12â€Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache, 2017, 57, 60-70.	1.8	38
75	Mindfulness and headache: A "new―old treatment, with new findings. Cephalalgia, 2016, 36, 1192-1205.	1.8	49
76	Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. Journal of Headache and Pain, 2016, 17, 91.	2.5	57
77	Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurological Sciences, 2016, 37, 1979-1986.	0.9	14
78	The multimodal treatment in headaches. Journal of Headache and Pain, 2015, 16, A47.	2.5	4
79	P031. An observational study on chronic tension-type headache treatment with Quantum Molecular Resonance according to I.A.R.A. model®. Journal of Headache and Pain, 2015, 16, A176.	2.5	13
80	Non invasive neurostimulation. Journal of Headache and Pain, 2015, 16, A18.	2.5	0
81	Disability, ICF biopsychosocial model and burden of migraine. Journal of Headache and Pain, 2015, 16, A2.	2.5	5
82	Disability and quality of life in patients with different forms of migraine. Journal of Headache and Pain, 2015, 16, A4.	2.5	6
83	A proposal for a national registry on chronic migraines. Journal of Headache and Pain, 2015, 16, A40.	2.5	1
84	Proposal of a model for multidisciplinary treatment program of chronic migraine with medication overuse: preliminary study. Neurological Sciences, 2015, 36, 169-171.	0.9	4
85	Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. Journal of Headache and Pain, 2015, 16, 61.	2.5	121
86	Chronic migraine with medication overuse: Association between disability and quality of life measures, and impact of disease on patients' lives. Journal of the Neurological Sciences, 2015, 348, 60-66.	0.3	34
87	Role of neurostimulation in migraine. Neurological Sciences, 2015, 36, 121-123.	0.9	5
88	Difficulties in work activities and the pervasive effect over disability in patients with episodic and chronic migraine. Neurological Sciences, 2015, 36, 9-11.	0.9	28
89	Approaches to treatments of chronic migraine associated with medication overuse: a comparison between different intensity regimens. Neurological Sciences, 2015, 36, 5-8.	0.9	7
90	Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurological Sciences, 2015, 36, 33-35.	0.9	32

#	Article	IF	Citations
91	Are Depressive Symptomatology, Selfâ€Efficacy, and Perceived Social Support Related to Disability and Quality of Life in Patients With Chronic Migraine Associated to Medication Overuse? Data From a Crossâ€Sectional Study. Headache, 2015, 55, 636-645.	1.8	27
92	EHMTI-0037. Botulinum A toxin for treatment of chronic migraine. Journal of Headache and Pain, 2014, 15, .	2.5	0
93	EHMTI-0036. Gammacore device for treatment of migraine attack: preliminary report. Journal of Headache and Pain, 2014, 15, .	2.5	8
94	Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurology, 2014, 14, 181.	0.8	22
95	Emerging Therapies for Chronic Migraine. Current Pain and Headache Reports, 2014, 18, 408.	1.3	6
96	Difficulties in work-related activities among migraineurs are scarcely collected: results from a literature review. Neurological Sciences, 2014, 35, 23-26.	0.9	19
97	Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurological Sciences, 2014, 35, 37-39.	0.9	14
98	Biofeedback and behavioral treatments: filling some gaps. Neurological Sciences, 2014, 35, 121-127.	0.9	14
99	Evaluation of immune parameters in chronic migraine with medication overuse. Neurological Sciences, 2014, 35, 171-173.	0.9	17
100	Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Quality of Life Research, 2014, 23, 1273-1277.	1.5	25
101	Day-hospital withdrawal for chronic migraine with medication overuse: results at 3Âyears follow-up. Neurological Sciences, 2013, 34, 167-169.	0.9	5
102	Onabotulinum toxin A for treatment of chronic migraine with medication overuse. Neurological Sciences, 2013, 34, 27-28.	0.9	7
103	Multidisciplinary approach to patients with chronic migraine and medication overuse: experience at the Besta Headache Center. Neurological Sciences, 2013, 34, 19-21.	0.9	8
104	A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurological Sciences, 2013, 34, 139-140.	0.9	6
105	Understanding the relationship between pain and emotion in idiopathic headaches. Neurological Sciences, 2013, 34, 29-31.	0.9	8
106	Disability and quality of life in headache: where we are now and where we are heading. Neurological Sciences, 2013, 34, 1-5.	0.9	24
107	Psychiatric screening for migraine patients. Neurological Sciences, 2013, 34, 61-66.	0.9	5
108	Pain, Emotion, Headache. Headache, 2012, 52, 98-101.	1.8	17

#	Article	IF	CITATIONS
109	In Medicationâ€Overuse Headache, <scp>fMRI</scp> Shows Longâ€Lasting Dysfunction in Midbrain Areas. Headache, 2012, 52, 1520-1534.	1.8	58
110	Orbitofrontal Dysfunction and Medication Overuse in Patients With <scp>M</scp> igraine. Headache, 2012, 52, 1511-1519.	1.8	25
111	Headaches and Arnold-Chiari Syndrome: When to Suspect and How to Investigate. Current Pain and Headache Reports, 2012, 16, 350-353.	1.3	10
112	Decision-making deficit in chronic migraine patients with medication overuse. Neurological Sciences, 2012, 33, 151-155.	0.9	19
113	Medication overuse headache (MOH): complication of migraine or secondary headache?. Neurological Sciences, 2012, 33, 27-28.	0.9	7
114	Headache, eating and sleeping behaviors and lifestyle factors in preadolescents and adolescents: preliminary results from an Italian population study. Neurological Sciences, 2012, 33, 87-90.	0.9	25
115	Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurological Sciences, 2012, 33, 169-171.	0.9	17
116	Pain Processing in Medication Overuse Headache: A Functional Magnetic Resonance Imaging (fMRI) Study. Pain Medicine, 2012, 13, 255-262.	0.9	74
117	The Reliability and Validity of the Visual Analog Mood Scales in Nonâ€Englishâ€5peaking Pain Patients. Pain Practice, 2012, 12, 626-632.	0.9	12
118	Restless legs syndrome is not associated with migraine with aura: a clinical study. Neurological Sciences, 2011, 32, 153-156.	0.9	22
119	Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurological Sciences, 2011, 32, 197-199.	0.9	34
120	Disability in chronic daily headache: state of the art and future directions. Neurological Sciences, 2011, 32, 71-76.	0.9	30
121	What future for treatment of chronic migraine with medication overuse?. Neurological Sciences, 2011, 32, 19-22.	0.9	6
122	Evolution of headache in a population of young Italian headache sufferers: a brief report. Neurological Sciences, 2011, 32, 193-195.	0.9	3
123	Headache and Chiari malformation in young age: clinical aspects and differential diagnosis. Neurological Sciences, 2011, 32, 299-301.	0.9	9
124	Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 2011, 31, 144-151.	1.8	30
125	Neuroimaging in chronic migraine. Neurological Sciences, 2010, 31, 19-22.	0.9	38
126	Headache in young age: classification of primary forms. Neurological Sciences, 2010, 31, 77-79.	0.9	3

#	Article	IF	Citations
127	Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurological Sciences, 2010, 31, 115-119.	0.9	14
128	Non-pharmacological approaches in migraine prophylaxis: behavioral medicine. Neurological Sciences, 2010, 31, 133-135.	0.9	13
129	An innovative approach for migraine prevention in young age: a preliminary study. Neurological Sciences, 2010, 31, 181-183.	0.9	20
130	Disability in chronic migraine with medication overuse: Treatment effects through 5 years. Cephalalgia, 2010, 30, 610-614.	1.8	45
131	Microembolic Air Load During Contrastâ€₹ranscranial Doppler: A Trigger for Migraine With Aura?. Headache, 2010, 50, 1320-1327.	1.8	36
132	Chronic Migraine With Medication Overuse Pre–Post Withdrawal of Symptomatic Medication: Clinical Results and fMRI Correlations. Headache, 2010, 50, 998-1004.	1.8	68
133	Prevalence and characteristics of right-to-left shunt in migraine with aura: a survey on 120 Italian patients. Neurological Sciences, 2009, 30, 109-111.	0.9	9
134	Behavioral plus pharmacological treatment versus pharmacological treatment only for chronic migraine with medication overuse after day-hospital withdrawal. Neurological Sciences, 2009, 30, 117-119.	0.9	15
135	Psychological variables in chronic migraine with medication overuse before and after inpatient withdrawal: results at 1-year follow-up. Neurological Sciences, 2009, 30, 125-127.	0.9	18
136	Functional-MRI evaluation of pain processing in chronic migraine with medication overuse. Neurological Sciences, 2009, 30, 71-74.	0.9	22
137	Treatment of chronic migraine with medication overuse: is drug withdrawal crucial?. Neurological Sciences, 2009, 30, 85-88.	0.9	38
138	Non-pharmacological approaches to treating chronic migraine with medication overuse. Neurological Sciences, 2009, 30, 89-93.	0.9	27
139	Behavioral medicine for migraine and medication overuse headache. Current Pain and Headache Reports, 2009, 13, 241-248.	1.3	33
140	Caliber Fluctuations of Cervical Internal Carotid Artery and Migraine With Aura: A Possible Vasospasm Detected by Ultrasonographic Examinations. Headache, 2009, 49, 1068-1072.	1.8	3
141	Headache with medication overuse: treatment strategies and proposals of relapse prevention. Neurological Sciences, 2008, 29, 93-98.	0.9	14
142	When should "chronic migraine―patients be considered "refractory―to pharmacological prophylaxis?. Neurological Sciences, 2008, 29, 55-58.	0.9	26
143	Therapeutic neurostimulation in chronic headaches: problems of patient selection. Neurological Sciences, 2008, 29, 59-61.	0.9	13
144	Behavioural approach to the "difficult―patient. Neurological Sciences, 2008, 29, 96-98.	0.9	3

#	Article	IF	CITATIONS
145	In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up. Neurological Sciences, 2008, 29, 161-163.	0.9	41
146	Homocysteine plasma levels in patients with migraine with aura. Neurological Sciences, 2008, 29, 173-175.	0.9	48
147	Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurological Sciences, 2008, 29, 176-178.	0.9	11
148	Disability in Chronic Migraine With Medication Overuse: Treatment Effects at 3 Years. Headache, 2007, 47, 1277-1281.	1.8	31
149	Behavioural treatments: rationale and overview of the most common therapeutic protocols. Neurological Sciences, 2007, 28, S67-S69.	0.9	5
150	Chronic headaches: pharmacological and non-pharmacological treatment. Neurological Sciences, 2007, 28, S134-S137.	0.9	8
151	Pharmacological treatment compared to behavioural treatment for juvenile tension-type headache: results at two-year follow-up. Neurological Sciences, 2007, 28, S235-S238.	0.9	30
152	Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up. Neurological Sciences, 2007, 28, 148-150.	0.9	31
153	Chronic headaches: pharmacological and non-pharmacological treatment. Neurological Sciences, 2006, 27, s174-s178.	0.9	1
154	Medication-overuse headache: Description, treatment, and relapse prevention. Current Pain and Headache Reports, 2006, 10, 71-77.	1.3	20
155	Topiramate in the prevention of migraine: a review of its efficacy, tolerability, and acceptability. Neuropsychiatric Disease and Treatment, 2006, 2, 261-267.	1.0	9
156	Disability Pattern in Chronic Migraine With Medication Overuse: A Comparison With Migraine Without Aura. Headache, 2005, 45, 553-560.	1.8	50
157	Magnesium as a treatment for paediatric tension-type headache: a clinical replication series. Neurological Sciences, 2005, 25, 338-341.	0.9	17
158	Facial pain in children and adolescents. Neurological Sciences, 2005, 26, s101-s103.	0.9	12
159	Migraine with aura from pathophysiology to treatment: therapeutic strategies. Neurological Sciences, 2005, 26, s104-s107.	0.9	7
160	Topiramate in migraine prophylaxis. Neurological Sciences, 2005, 26, s130-s133.	0.9	18
161	Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurological Sciences, 2005, 26, s162-s166.	0.9	45
162	Selective vs. Complete Family Interview for Detecting those Affected by Familial Cluster Headache. Cephalalgia, 2004, 24, 938-939.	1.8	3

#	Article	IF	CITATIONS
163	Disability in Chronic Migraine Patients With Medication Overuse: Treatment Effects at 1â€Year Followâ€up. Headache, 2004, 44, 678-683.	1.8	45
164	Disability and quality of life in different primary headaches: results from Italian studies. Neurological Sciences, 2004, 25, s105-s107.	0.9	68
165	Measuring responses to therapy in headache patients: new and traditional end-points. Neurological Sciences, 2004, 25, s108-s110.	0.9	3
166	Disability in young patients suffering from primary headaches. Neurological Sciences, 2004, 25, s111-s112.	0.9	6
167	Strategies for the treatment of autonomic trigeminal cephalalgias. Neurological Sciences, 2004, 25, s167-s170.	0.9	7
168	Headache in children and adolescents: conventional and unconventional approaches to treatment. Neurological Sciences, 2004, 25, s223-s225.	0.9	4
169	Primary headaches in children and adolescents. Neurological Sciences, 2004, 25, s232-s233.	0.9	7
170	MIDAS questionnaire modification for a new MIDAS junior questionnaire: a clinical experience at the Neurological Institute ?C. Besta?. Neurological Sciences, 2004, 25, s261-s262.	0.9	0
171	Pharmacological behavioural treatment for children and adolescents with tension-type headache: preliminary data. Neurological Sciences, 2004, 25, s270-s271.	0.9	21
172	Chronic migraine with medication overuse: treatment outcome and disability at 3 years follow-up. Neurological Sciences, 2004, 25, s272-s273.	0.9	11
173	The Impact of Primary Headaches on Patients' Lives: Italian Experience with the MIDAS and the SF-36 Questionnaires. Headache Care, 2004, 1, 123-128.	0.2	11
174	Quality of life and disability in primary chronic daily headaches. Neurological Sciences, 2003, 24, s97-s100.	0.9	71
175	Chronic headache in young patients: clinical aspects and treatment suggestions. Neurological Sciences, 2003, 24, s112-s114.	0.9	2
176	Treatment of chronic daily headache with medication overuse. Neurological Sciences, 2003, 24, s125-s127.	0.9	3
177	Use of the Migraine Disability Assessment Questionnaire in Children and Adolescents With Headache: An Italian Pilot Study. Headache, 2003, 43, 767-773.	1.8	30
178	Topiramate in Cluster Headache Prophylaxis: an Open Trial. Cephalalgia, 2003, 23, 1001-1002.	1.8	95
179	Brief neurologist-administered behavioral treatment of pediatric episodic tension-type headache. Neurology, 2003, 60, 1215-1216.	1.5	29
180	Behavioral and Pharmacologic Treatment of Transformed Migraine With Analgesic Overuse: Outcome at 3 Years. Headache, 2002, 42, 483-490.	1.8	164

#	Article	IF	CITATIONS
181	Increased Plasma Nitrites in Migraine and Cluster Headache Patients in Interictal Period: Basal Hyperactivity of L-Arginine-No Pathway?. Cephalalgia, 2002, 22, 33-36.	1.8	57
182	Health-Related Quality of Life in Patients with Cluster Headache During Active Periods. Cephalalgia, 2002, 22, 818-821.	1.8	63
183	Disability and migraine: MIDAS. Journal of Headache and Pain, 2001, 2, s25-s27.	2.5	5
184	Disability in migraine patients: Italian experience. Journal of Headache and Pain, 2001, 2, s29-s31.	2.5	4
185	The serotonergic system in migraine. Journal of Headache and Pain, 2001, 2, s43-s46.	2.5	2
186	Menstrual migraine. Journal of Headache and Pain, 2001, 2, s117-s119.	2.5	1
187	Electromyographic Biofeedback-Assisted Relaxation Training in Juvenile Episodic Tension-Type Headache: Clinical Outcome at Three-Year Follow-Up the in of and for on with at is an as by. Cephalalgia, 2001, 21, 798-803.	1.8	43
188	The Migraine Disability Assessment (MIDAS) Questionnaire: Translation and Reliability of the Italian Version. Cephalalgia, 2001, 21, 947-952.	1.8	145
189	Increased familial risk of cluster headache. Neurology, 2001, 56, 1233-1236.	1.5	123
190	Two New SUNCT Cases Responsive to Lamotrigine. Cephalalgia, 2000, 20, 845-847.	1.8	80
191	An Italian pilot study on the use of the migraine disability assessment questionnaire. Journal of Headache and Pain, 2000, 1, 47-51.	2.5	3
192	The importance of anxiety and depression as factors in chronicization of primary headaches. Journal of Headache and Pain, 2000, 1 , S45-S48.	2.5	14
193	Quality of life and illness behaviour in chronic daily headache patients. Journal of Headache and Pain, 2000, 1, S61-S65.	2.5	2
194	Chronic daily headache: personality study by means of computerized MMPI-2. Journal of Headache and Pain, 2000, 1, S67-S70.	2.5	7
195	The serotonergic agent <i>m</i> -chlorophenylpiperazine induces migraine attacks: A controlled study. Neurology, 2000, 55, 136-139.	1.5	39
196	Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo. Neurology, 2000, 54, 1382-1385.	1.5	223
197	Trigeminal autonomic cephalgia with periorbital ecchymosis, ocular hemorrhage, hypertension and behavioral alterations. Pain, 2000, 88, 109-112.	2.0	21
198	Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo. Cephalalgia, 1999, 19, 232-240.	1.8	106

#	Article	IF	Citations
199	alpha-Dihydroergocryptine in the Prophylaxis of Migraine: A Multicenter Double-Blind Study Versus Flunarizine. Headache, 1999, 39, 426-431.	1.8	27
200	Neuroendocrinology of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S18-S20.	0.1	14
201	Role of nitric oxide in cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S25-S27.	0.1	13
202	Pharmacological and behavioral treatment of pediatric migraine and tension-type headache. Italian Journal of Neurological Sciences, 1998, 19, 59-64.	0.1	6
203	Type II neurofibromatosis presenting as quadriceps atrophy. Italian Journal of Neurological Sciences, 1998, 19, 94-96.	0.1	10
204	A review of the treatment of primary headaches. Part II: Tension-type headache. Italian Journal of Neurological Sciences, 1998, 19, 2-9.	0.1	7
205	Cervicogenic headache: a critical review of the current diagnostic criteria. Pain, 1998, 78, 1-5.	2.0	84
206	Biofeedback-assisted relaxation training for young adolescents with tension-type headache: a controlled study. Cephalalgia, 1998, 18, 463-467.	1.8	84
207	Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?. Cephalalgia, 1998, 18, 618-621.	1.8	59
208	Abnormal 24-hour urinary excretory pattern of 6-sulphatoxymelatonin in both phases of cluster headache. Cephalalgia, 1998, 18, 664-667.	1.8	48
209	5-HT1A Receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. NeuroReport, 1998, 9, 2605-2608.	0.6	30
210	Coexistence of Migraine and Cluster Headache: Report of 10 Cases and Possible Pathogenetic Implications. Headache, 1997, 37, 21-25.	1.8	39
211	Sumatriptan in the Acute Treatment of Migraine Without Aura: Efficacy of 50-mg Dose. Headache, 1997, 37, 421-423.	1.8	9
212	Transdermal Clonidine in the Prophylaxis of Episodic Cluster Headache: An Open Study. Headache, 1997, 37, 559-560.	1.8	27
213	Transdermal Clonidine in the Prophylaxis of Episodic Cluster Headache. Cephalalgia, 1997, 17, 551-551.	1.8	4
214	The M-Chlorophenylpiperazine Test in Cluster Headache. Cephalalgia, 1997, 17, 666-672.	1.8	24
215	A review of the treatment of primary headaches. Part I: Migraine. Italian Journal of Neurological Sciences, 1995, 16, 577-586.	0.1	8
216	Internal Ophthalmoplegia Associated with Migraine Attacks. Cephalalgia, 1994, 14, 461-462.	1.8	5

#	Article	IF	CITATIONS
217	Effect of Biofeedback Treatment on Sympathetic Function in Common Migraine and Tension-Type Headache. Cephalalgia, 1993, 13, 197-200.	1.8	15
218	Italian Experience of Electromyographic-Biofeedback Treatment of Episodic Common Migraine: Preliminary Results. Headache, 1993, 33, 439-441.	1.8	14
219	Physical Effort-Induced Changes in Immune Parameters. International Journal of Neuroscience, 1993, 68, 133-140.	0.8	5
220	Short and Medium-Term Influence of Physical Activity on Immune Parametersa. International Journal of Neuroscience, 1993, 71, 267-276.	0.8	2
221	EMG-BFB Treatment and Sympathetic Indexes Changes in Common Migraine. Cephalalgia, 1991, 11, 141-142.	1.8	0
222	Immunological Study in Cluster Headache Cephalalgia, 1991, 11, 256-257.	1.8	0
223	Flunarizine in Migraine: A Minireview. Headache, 1991, 31, 388-391.	1.8	40
224	Dihydroergokryptine Versus Dihydroergotamine in Migraine Prophylaxis: A Double-Blind Clinical Trial. Cephalalgia, 1991, 11, 117-121.	1.8	9
225	Amelanotic leptomeningeal melanoblastosis. Case report. Italian Journal of Neurological Sciences, 1990, 11, 171-175.	0.1	2
226	A therapeutic alternative for tension headache in children: Treatment and 1-year follow-up results. Biofeedback and Self-regulation, 1990, 15, 1-6.	0.3	42
227	Role of Physical Training on Immune Function: Preliminary Data. International Journal of Neuroscience, 1990, 51, 249-252.	0.8	3
228	Derangement of the Hypothalamo-Pituitary Axis (HPa) in Cluster Headache: Further Considerations. Cephalalgia, 1989, 9, 141-142.	1.8	1
229	Neurobrucellosis Mimicking Multiple Sclerosis: A Case Report. European Neurology, 1989, 29, 238-240.	0.6	24
230	Cluster Headache Patients' Responses to Dexamethasone Suppression Test. Headache, 1988, 28, 130-132.	1.8	11
231	Psychological Assessment in Tension Headache Before and After Biofeedback Treatment. Headache, 1988, 28, 337-338.	1.8	10
232	Internal Ophthalmoplegia in Complicated Migraine: A Case Report. Headache, 1987, 27, 489-490.	1.8	7